ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 814

NON Diffuse SSc, Peripheral Neuropathy, Concomitant Sjogren Syndrome and ANTI-RNA Polymerase III Represent Risk Factors for the Higher Frequency of Cancer in a Large Single Cohort of Patients with Systemic Sclerosis

Ana Paula Luppino-Assad1, Adriana Bortoluzzo2, Henrique Carriço da Silva3, Danieli Andrade4 and Percival Sampaio-Barros4, 1Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., sao paulo, Brazil, 2c Instituto Insper de Educação e Pesquisa, São Paulo, SP, Brasil, sao paulo, Brazil, 3Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., SAO PAULO, Brazil, 4Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., São Paulo, Brazil

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Antibodies, Cancer, Malignancy, scleroderma and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Systemic Sclerosis and Related Disorders – Clinical Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: A higher prevalence of cancer has been described in patients with systemic sclerosis (SSc), but the magnitude of this risk and the type of cancer vary among reports. Risk factors predisposing the development of malignancies in SSc patients are not well defined. The purpose of our study was to analyze the frequency and risk factors associated with cancer in a large single cohort of patients with SSc.

Methods: All cases of cancer diagnosed in a cohort of 662 patients classified as SSc according to the ACR/EULAR criteria, attended in a single referral scleroderma outpatient clinic in Brazil between 2010 and 2017, were reviewed and evaluated regarding demographic, clinical and laboratory features. We used the Brazilian National Cancer Institute database to compare the cancer prevalence in SSc patients with the expected rate of cancer in the general population, and to estimate the risk of each cancer in this group, pairing by age. Taking into account that all sample proportions have an observed incidence higher than the general population, the one-tail proportion test was used to compare the cancer incidence in the sample and the population. A logistic regression model was performed to find risk factors for cancer. Statistical significance was considered when p ≤ 0.05.

Results: ±± 13.91 years; p ≤±±±±±± 9.24 years; p = 0.029). When the frequency of cancer by gender in the SSc patients was compared with the predicted frequency of cancer in the Brazilian general population, it was found a significant association among female gender and cancer in general (p<0.001), as well as with breast (p<0.001), uterus (p=0.023), lung (p=0.013), colon (p=0.007), esophagus (p=0.012), stomach (p = 0.042), lymphoma/leukemia (p=0.007), thyroid (p=0.004) and melanoma (p=0.022); male gender was only associated with cancer in general (p=0.013). Multivariate logistic regression identified non diffuse SSc (OR 10.7, 95%CI 2.1-54.8, p=0.004), Sjogren syndrome (OR 3.4, 95%CI 1,4-8.5, p=0.007), peripheral neuropathy (OR 4.4, 95%CI 1.5-13.2, p=0.009) and anti-RNApolIII positivity (OR 5.1, 95%CI 1.2-22.7, p=0.032) as significant risk factors for cancer occurrence.

Conclusion: This study confirmed a higher frequency of cancer in a large SSc cohort and pointed out that non diffuse SSc, peripheral neuropathy, concomitant Sjogren syndrome and anti-RNA polymerase III positivity represent risk factors for the development of cancer in SSc.


Disclosure: A. P. Luppino-Assad, None; A. Bortoluzzo, None; H. C. da Silva, None; D. Andrade, None; P. Sampaio-Barros, None.

To cite this abstract in AMA style:

Luppino-Assad AP, Bortoluzzo A, da Silva HC, Andrade D, Sampaio-Barros P. NON Diffuse SSc, Peripheral Neuropathy, Concomitant Sjogren Syndrome and ANTI-RNA Polymerase III Represent Risk Factors for the Higher Frequency of Cancer in a Large Single Cohort of Patients with Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/non-diffuse-ssc-peripheral-neuropathy-concomitant-sjogren-syndrome-and-anti-rna-polymerase-iii-represent-risk-factors-for-the-higher-frequency-of-cancer-in-a-large-single-cohort-of-patients-with-sys/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/non-diffuse-ssc-peripheral-neuropathy-concomitant-sjogren-syndrome-and-anti-rna-polymerase-iii-represent-risk-factors-for-the-higher-frequency-of-cancer-in-a-large-single-cohort-of-patients-with-sys/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology